These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 36332589)

  • 1. Buprenorphine treatment episode duration, dosage, and concurrent prescribing of benzodiazepines and opioid analgesics: The effects of Medicaid prior authorization policies.
    Landis RK; Opper I; Saloner B; Gordon AJ; Leslie DL; Sorbero M; Stein BD
    Drug Alcohol Depend; 2022 Dec; 241():109669. PubMed ID: 36332589
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sociodemographic differences in quality of treatment to Medicaid enrollees receiving buprenorphine.
    Landis RK; Levin JS; Saloner B; Gordon AJ; Dick AW; Sherry TB; Leslie DL; Sorbero M; Stein BD
    Subst Abus; 2022 Dec; 43(1):1057-1071. PubMed ID: 35442178
    [No Abstract]   [Full Text] [Related]  

  • 3. The association of Medicare Part D prior authorization for buprenorphine-naloxone with adherence to opioid use disorder treatment guidelines in the United States.
    Parish WJ; Mark TL; Zarkin GA; Weber E
    Addiction; 2022 Jan; 117(1):141-150. PubMed ID: 34033177
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Removal of Medicaid Prior Authorization Requirements and Buprenorphine Treatment for Opioid Use Disorder.
    Christine PJ; Larochelle MR; Lin LA; McBride J; Tipirneni R
    JAMA Health Forum; 2023 Oct; 4(10):e233549. PubMed ID: 37862034
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differences in buprenorphine treatment quality across physician provider specialties.
    Levin JS; Landis RK; Sorbero M; Dick AW; Saloner B; Stein BD
    Drug Alcohol Depend; 2022 Aug; 237():109510. PubMed ID: 35753279
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of Medications for Treatment of Opioid Use Disorder Among US Medicaid Enrollees in 11 States, 2014-2018.
    ; Donohue JM; Jarlenski MP; Kim JY; Tang L; Ahrens K; Allen L; Austin A; Barnes AJ; Burns M; Chang CH; Clark S; Cole E; Crane D; Cunningham P; Idala D; Junker S; Lanier P; Mauk R; McDuffie MJ; Mohamoud S; Pauly N; Sheets L; Talbert J; Zivin K; Gordon AJ; Kennedy S
    JAMA; 2021 Jul; 326(2):154-164. PubMed ID: 34255008
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exploring the Association of State Policies and the Trajectories of Buprenorphine Prescriber Patient Caseloads.
    Griffin BA; Cabreros I; Saloner B; Gordon AJ; Kerber R; Stein BD
    Subst Abus; 2023 Jul; 44(3):136-145. PubMed ID: 37401501
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Buprenorphine Treatment For Opioid Use Disorder: Comparison Of Insurance Restrictions, 2017-21.
    Andraka-Christou B; Simon KI; Bradford WD; Nguyen T
    Health Aff (Millwood); 2023 May; 42(5):658-664. PubMed ID: 37126752
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Are North Carolina clinicians delivering opioid use disorder treatment to Medicaid beneficiaries?
    Grove LR; Rao N; Domino ME
    Addiction; 2022 Nov; 117(11):2855-2863. PubMed ID: 35194878
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Health care use and spending for Medicaid patients diagnosed with opioid use disorder receiving primary care in Federally Qualified Health Centers and other primary care settings.
    Peterson L; Murugesan M; Nocon R; Hoang H; Bolton J; Laiteerapong N; Pollack H; Marsh J
    PLoS One; 2022; 17(10):e0276066. PubMed ID: 36256662
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of CARA mandates on nurse practitioner controlled substance prescribing in Oregon: a cohort study.
    Klein TA; Hartung D; Markwardt S
    Subst Abuse Treat Prev Policy; 2022 Jan; 17(1):5. PubMed ID: 35101077
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Psychosocial and behavioral therapy in conjunction with medication for opioid use disorder: Patterns, predictors, and association with buprenorphine treatment outcomes.
    Samples H; Williams AR; Crystal S; Olfson M
    J Subst Abuse Treat; 2022 Aug; 139():108774. PubMed ID: 35337716
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of Medicaid expansion on use of opioid agonist treatment and the role of provider capacity constraints.
    Gertner AK; Robertson AG; Jones H; Powell BJ; Silberman P; Domino ME
    Health Serv Res; 2020 Jun; 55(3):383-392. PubMed ID: 32166761
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Duration of medication treatment for opioid-use disorder and risk of overdose among Medicaid enrollees in 11 states: a retrospective cohort study.
    Burns M; Tang L; Chang CH; Kim JY; Ahrens K; Allen L; Cunningham P; Gordon AJ; Jarlenski MP; Lanier P; Mauk R; McDuffie MJ; Mohamoud S; Talbert J; Zivin K; Donohue J
    Addiction; 2022 Dec; 117(12):3079-3088. PubMed ID: 35652681
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral buprenorphine utilization, concomitant benzodiazepines and opioid analgesics, and payment source: Trends from 2015 to 2019.
    Ijioma SC; Chilcoat HD; DeVeaugh-Geiss AM
    J Subst Use Addict Treat; 2023 Apr; 147():208980. PubMed ID: 36841074
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Medicaid Prescription Cap Policies: Another Structural Barrier to Medication for Opioid Use Disorder.
    Hughto JMW; Moyo P; Green TC
    J Addict Med; 2022 Nov-Dec 01; 16(6):616-618. PubMed ID: 35245915
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Buprenorphine Utilization and Prescribing Among New Jersey Medicaid Beneficiaries After Adoption of Initiatives Designed to Improve Treatment Access.
    Treitler P; Nowels M; Samples H; Crystal S
    JAMA Netw Open; 2023 May; 6(5):e2312030. PubMed ID: 37145594
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Opioid use disorder treatment and the role of New Jersey Medicaid policy changes: perspectives of office-based buprenorphine providers.
    Mahone A; Enich M; Treitler P; Lloyd J; Crystal S
    Am J Drug Alcohol Abuse; 2023 Sep; 49(5):606-617. PubMed ID: 37506336
    [No Abstract]   [Full Text] [Related]  

  • 19. The impact of prior authorization on buprenorphine dose, relapse rates, and cost for Massachusetts Medicaid beneficiaries with opioid dependence.
    Clark RE; Baxter JD; Barton BA; Aweh G; O'Connell E; Fisher WH
    Health Serv Res; 2014 Dec; 49(6):1964-79. PubMed ID: 25040021
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Buprenorphine prescribing for opioid use disorder in medical practices: can office-based out-patient care address the opiate crisis in the United States?
    Rhee TG; Rosenheck RA
    Addiction; 2019 Nov; 114(11):1992-1999. PubMed ID: 31307111
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.